Obesity and Breast Cancer: How Inflammation Affects Treatment Sensitivity
Author Information
Author(s): Morla-Barcelo Pere Miquel, Melguizo-Salom Lucas, Roca Pilar, Nadal-Serrano Mercedes, Sastre-Serra Jorge, Torrens-Mas Margalida
Primary Institution: Institut Universitari d’Investigació en Ciències de la Salut (IUNICS), Universitat de les Illes Balears
Hypothesis
Obesity-related inflammation reduces treatment sensitivity and promotes aggressiveness in luminal breast cancer by modulating oxidative stress and mitochondrial function.
Conclusion
The study suggests that obesity-related inflammation decreases treatment sensitivity in luminal breast cancer by affecting antioxidant and mitochondrial markers.
Supporting Evidence
- Obesity is linked to a 39% increased likelihood of developing breast cancer.
- ELIT exposure increased mammosphere formation in luminal breast cancer cell lines.
- 3D-derived T47D cells showed reduced sensitivity to tamoxifen and paclitaxel after ELIT exposure.
- Specific biomarkers correlated with poor prognosis in luminal breast cancer were identified.
Takeaway
Being overweight can make breast cancer treatments less effective because it changes how cancer cells behave and respond to drugs.
Methodology
The study used a 3D culture model to investigate the effects of an ELIT cocktail on breast cancer cell lines, focusing on mammosphere formation, oxidative stress, and treatment sensitivity.
Potential Biases
Potential biases may arise from the specific cell lines used and the in vitro nature of the study.
Limitations
The study primarily focused on specific breast cancer cell lines and may not fully represent all breast cancer types.
Participant Demographics
The study analyzed data from 16 obese and 10 lean luminal breast cancer patients.
Statistical Information
P-Value
p = 0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website